The study, conducted by researchers from Insilico Medicine, the University of Chicago, and Johns Hopkins University, addresses a central challenge in rare-cancer research: there are often too few patients, tissue samples, and molecular datasets to support the conventional process of identifying drug targets. Instead of relying on a single genetic alteration or a large population study, the investigators combined multiple layers of biological information to reconstruct how IP-SNSCC evolves and to identify molecular vulnerabilities that could guide future treatment development.

IP-SNSCC arises from inverted papillomas, benign but locally aggressive tumors that form in the sinonasal tract. In a subset of patients, these lesions progress into squamous cell carcinoma, a malignant disease capable of invading surrounding tissue and spreading. Surgery and radiation remain central to treatment, but therapeutic options are limited once the cancer becomes advanced or recurrent. Because the disease is so uncommon, it has received far less molecular research than more prevalent cancers, leaving clinicians with few targeted strategies.

To follow the transition from benign growth to invasive cancer, the researchers examined matched samples representing normal tissue, inverted papilloma, and carcinoma. They analyzed whole-exome sequencing to identify changes in protein-coding regions of the genome, RNA sequencing to measure gene activity, and mitochondrial DNA sequencing to investigate alterations in the cell’s energy-producing organelles. Studying these sample stages together allowed the team to distinguish changes associated with malignant progression from molecular features that may simply reflect a patient’s normal genetic background.

The results did not point to one dominant mutation responsible for the disease. Instead, they revealed a coordinated biological shift involving several interconnected systems. Abnormalities in cell-cycle regulation suggested that cancer cells were acquiring greater capacity for uncontrolled growth. Changes in extracellular matrix remodeling indicated that the tissue environment was being reorganized in ways that could help tumor cells invade nearby structures. Disrupted immune signaling pointed to altered communication between malignant cells and the immune system, while metabolic reprogramming suggested that tumor cells were changing how they generate and use energy.

This pattern is important because cancer biology is often driven not by a single defective gene but by networks of interacting pathways. A tumor may compensate when one pathway is blocked, making isolated genetic findings difficult to translate into treatment. By examining gene expression, genetic variation, mitochondrial alterations, signaling pathways, and protein networks together, the study offers a more detailed view of the biological machinery that supports IP-SNSCC. The resulting molecular profile could serve as a reference point for researchers investigating how the disease begins, progresses, and responds to therapy.

The team then used PandaOmics, Insilico Medicine’s artificial-intelligence platform for biological target discovery, to prioritize potential treatment targets. Its TargetID algorithms integrated the study’s transcriptomic data with pathway-level biology, protein–protein interaction networks, genetic evidence, and assessments of whether candidate proteins could realistically be targeted by drugs. This approach is designed to convert a complex molecular dataset into a ranked set of biological hypotheses, helping researchers focus experimental resources on the most promising opportunities.

Among the prioritized candidates were proteins already targeted by approved medicines, raising the possibility that some existing drugs could eventually be evaluated for repurposing in IP-SNSCC. The analysis also highlighted previously unexplored targets that could support new drug-discovery programs designed specifically for this cancer. These findings do not establish that any candidate will benefit patients, and the researchers emphasized that laboratory studies, independent validation, and clinical trials will be required before therapeutic conclusions can be drawn. Nevertheless, the work demonstrates how AI can help overcome the “small data” problem that has historically slowed research into rare diseases.

Alex Zhavoronkov, PhD, founder and chief executive officer of Insilico Medicine and co-corresponding author of the study, said that combining comprehensive multi-omic profiling with PandaOmics enabled the team to generate actionable therapeutic hypotheses in a disease where conventional approaches have struggled. The study’s broader significance extends beyond sinonasal cancer: it presents a potential framework for investigating other rare malignancies in which patient numbers are small but the need for effective treatment is substantial. By linking molecular evolution to druggability, the researchers hope to move rare-cancer research more rapidly from biological description toward translational testing.

The paper, titled “Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma–associated sinonasal squamous cell carcinoma,” was published online in npj Precision Oncology on July 10, 2026. Insilico Medicine, a clinical-stage biotechnology company, uses artificial intelligence and automated technologies in drug discovery programs spanning oncology, fibrosis, immunology, pain, obesity, metabolic disorders, and other fields. The company is listed on the Main Board of the Hong Kong Stock Exchange under the ticker 3696.

Subject of Research:
AI-assisted multi-omic analysis and therapeutic target discovery in inverted papilloma-associated sinonasal squamous cell carcinoma.

Article Title:
“Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma–associated sinonasal squamous cell carcinoma”

News Publication Date:
Aug. 4, 2026

References:
npj Precision Oncology; article publication date: July 10, 2026.

Keywords:
Generative AI, artificial intelligence, multi-omics, precision oncology, sinonasal squamous cell carcinoma, inverted papilloma, cancer research, drug discovery, target identification, PandaOmics.

This pivotal study, designated as Alliance A092204, explores the synergistic potential of cabozantinib and cemiplimab in halting or reversing the progression of ACC. Cabozantinib, an orally administered tyrosine kinase inhibitor (TKI), impedes cellular signaling pathways that promote cancer cell proliferation by targeting receptors involved in tumor growth and angiogenesis. Cemiplimab is a monoclonal antibody functioning as a programmed death receptor-1 (PD-1) immune checkpoint inhibitor, reinvigorating the immune system’s capacity to detect and destroy malignant cells. The rationale behind combining these agents lies in their complementary mechanisms of action, which may collectively enhance anti-tumor efficacy beyond what each drug can achieve individually.

Adrenocortical carcinoma is an uncommon neoplasm arising from the adrenal glands, which are located atop the kidneys and play a critical role in hormone production and regulation. Although adrenal tumors are relatively frequent, with incidental findings in approximately 10% of individuals undergoing imaging for other reasons, the vast majority of these lesions are benign and clinically insignificant. ACC, however, manifests as a highly malignant entity with an incidence estimated at about one person per million annually in the United States. The disease is often detected at advanced stages, rendering traditional interventions largely ineffective and underscoring the necessity for innovative therapeutic strategies.

Participants enrolled in this randomized controlled trial will be allocated to one of two treatment arms. The control arm receives cabozantinib monotherapy; this TKI exerts its anti-cancer effects primarily by inhibiting MET and VEGFR2 kinase activity, thereby disrupting tumor cell signaling and tumor-associated angiogenesis. The investigational arm receives a combination regimen of cabozantinib plus cemiplimab, the latter delivering systemic immunomodulation by lifting immune checkpoint blockade, allowing cytotoxic T-cells to more effectively target tumor cells. Researchers hypothesize that this combination may provoke a more robust tumor response due to the augmented immune-mediated attack coupled with the inhibition of oncogenic signaling.

Treatment durations in the study are planned for up to 24 months contingent upon evidence of clinical benefit and manageable adverse events. Efficacy endpoints include progression-free survival (PFS), which measures the time patients remain free from disease worsening, and overall survival (OS), reflecting the length of time patients live following treatment initiation. Tumor response rates and durability of response will be assessed using standardized imaging and clinical criteria. Safety profiles will be rigorously monitored to detect potential toxicities stemming from each agent alone or their combined administration.

Dr. Bhavana Konda, MD, MPH, Section Chief of Neuroendocrine Tumors and Endocrine Medical Oncology at The Ohio State University Comprehensive Cancer Center and chair of the study, emphasizes the critical nature of this investigation. She notes, “Few effective treatments exist for this devastating cancer. By probing the combination of targeted therapy and immunotherapy, this trial endeavors to enhance disease control and quality of life for patients facing this formidable diagnosis.” Her leadership exemplifies the commitment to advancing therapeutic horizons in oncology, particularly for rare tumor types neglected by prior research efforts.

The underlying biology of ACC involves aberrant cell signaling pathways that drive unchecked tumor growth and metastatic potential. Tyrosine kinase enzymes such as MET and VEGFR2 are instrumental in modulating cell proliferation, migration, and angiogenesis. Meanwhile, tumor cells often evade immune surveillance through upregulation of PD-1/PD-L1 checkpoint pathways that suppress T-cell activity. Combining a TKI with a PD-1 inhibitor therefore offers a compelling dual-pronged approach: blocking tumor-promoting signals while simultaneously unleashing an anti-tumor immune response.

Challenges in treating ACC are multifaceted, including the tumor’s intrinsic resistance to chemotherapy and radiotherapy, as well as its capacity for rapid dissemination. The paucity of patient populations for clinical research further complicates trial design and recruitment. Hence, the Alliance’s effort is especially noteworthy given its extensive network of oncology specialists and research infrastructure, which enables the aggregation of sufficient data to rigorously evaluate this innovative therapeutic concept in a rare disease context.

The investigational agent cemiplimab serves as a groundbreaking immunotherapy approved for multiple cancers, demonstrating durable responses by interrupting immune checkpoints that tumor cells exploit to avoid immune destruction. Its integration into ACC treatment paradigms marks a transformative step, potentially redefining standard care for a malignancy long underserved by modern oncology advances. Concurrently, cabozantinib’s inhibitory activity on multiple kinases offers the promise of targeting redundant signaling pathways crucial for ACC survival and progression.

By measuring outcomes including PFS, OS, tumor regression, and treatment-related adverse effects, this trial aims to delineate not only the clinical benefit but also the safety and tolerability of the drug combination. Data generated will provide insights that may inform future treatment guidelines, influence regulatory approval processes, and inspire subsequent trials incorporating other immunotherapeutic or targeted agents, ultimately contributing to personalized oncology strategies for ACC patients.

In summary, the Alliance A092204 study epitomizes a pioneering effort to surmount the therapeutic challenges posed by advanced adrenocortical carcinoma. Through a scientifically rational combination of cabozantinib and cemiplimab, this trial holds the potential to extend survival, ameliorate symptoms, and improve life quality for individuals afflicted by this rare and lethal cancer. It exemplifies the power of collaborative oncological research to innovate and bring hope where treatment options have traditionally been scarce.

Subject of Research: People
Article Title: Not provided
News Publication Date: Not provided
Web References: Alliance A092204 Clinical Trial
References: Alliance A0922014/NCT06900595 – Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer.
Image Credits: Courtesy The Ohio State University
Keywords: Clinical trials, Medical treatments, Antibody therapy, Immunotherapy, Drug studies, Clinical medicine, Cancer immunotherapy, Tyrosine kinase inhibitors, Cabozantinib, Cemiplimab, Adrenocortical carcinoma, Oncology, Tumor growth, Tumor regression